

FACTOR VII (ACTIVATED) RECOMBINANT

(eptacog alfa activated; rFVIIa; Niastase RT ®,)

CLASSIFICATION

- Coagulation factor

INDICATIONS

- Treatment of bleeding episodes (including treatment and prevention of those occurring during and after surgery) in patients with hemophilia A or B with inhibitors to factors VIII or IX.

ADMINISTRATION

- For IV use: powder vial and diluent (histidine solvent) should be at room temp before reconstitution. If not at room temp, hold vials to bring them to room temp. Reconstitute powder vial by adding 1.1 mL of diluent for the 1 mg vial, 2.1 mL of diluent for the 2 mg vial, 5.2 mL of diluent for the 5 mg vial and 8.1 mL of diluent for the 8 mg vial. Inject diluent slowly along wall of vial; Do NOT inject diluent directly onto the powder. Gently swirl until dissolved.
- IV direct: physician or RHCP. Administer over 2-5 minutes.

POTENTIAL ADMINISTRATION HAZARDS

- Hypersensitivity: rash, pruritus, anaphylaxis (rare).
- Cardiovascular: hypertension, hypotension, edema.
- GI: nausea, vomiting.
- CNS: headache.
- Hematologic: thrombotic events (arterial and venous), hemorrhage.
- Fever, pain.
- Local reactions: redness and pain at injection site.

DOSAGE

- Dosage will depend on the nature and severity of the coagulation defect, the site of bleeding and the type of intervention.
- 35-90 mcg/kg IV q2h until achievement of hemostasis; dosage interval may then be extended from 2 to 6 hours.

COMPATIBILITY, STABILITY

- Store powder vial and diluent at room temp or in the fridge (2-25°C). Do not freeze. Protect powder and diluent from light.
- Reconstituted vials are stable at room temp or in the fridge for a maximum of 3 hours.
- Do not mix with infusion solutions.

MISCELLANEOUS

- Known hypersensitivity to mouse, hamster or bovine proteins is a contraindication to the use of the product.

AVAILABILITY

- Factor VII (activated) is available from the Blood Bank.

REFERENCES

2, 95, 135.

2014 (KGH Revision Nov 2015)